Exelixis, Inc. Release: Cabozantinib to be Featured in Nine Presentations at the 2013 American Society of Clinical Oncology Annual Meeting

Published: May 08, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Exelixis, Inc. (NASDAQ:EXEL) announced today that cabozantinib will be the subject of nine separate data presentations at the upcoming 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will be held May 31-June 4, 2013, in Chicago, Illinois. Clinical data for cabozantinib will be featured in one oral presentation, one poster discussion, and seven general poster presentations.

Help employers find you! Check out all the jobs and post your resume.

Back to news